pharmaphorum3d
FDA says yes to MSD’s 21-valent adult pneumococcal jab
The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...
pharmaphorum5d
End of the line for MSD's TIGIT, LAG-3 cancer drugs
MSD has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline. The demise of the two ...
Morningstar23d
MS Emerging Markets Debt MSD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...